BillionToOne, Inc. Class A (BLLN)
NASDAQ:BLLN
Want to see BLLN full AI Analyst Report?
BLLN Stock Chart & Stats
$77.00
--
Market closed
$77.00
--
Day’s Range― - ―
52-Week Range$61.96 - $138.70
Previous CloseN/A
VolumeN/A
Average Volume (3M)637.67K
Market Cap
$3.96B
Enterprise Value$3.56B
Total Cash (Recent Filing)$537.45M
Total Debt (Recent Filing)$144.19M
Price to Earnings (P/E)50.4
Beta1.21
Next Earnings
Dec 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.51
Shares Outstanding41,442,833
10 Day Avg. Volume840,530
30 Day Avg. Volume637,669
Financial Highlights & Ratios
PEG Ratio-4.71
Price to Book (P/B)7.81
Price to Sales (P/S)12.29
P/FCF Ratio238.56
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue10.04
Enterprise Value/Gross Profit14.26
Enterprise Value/Ebitda86.26
Forecast
1Y Price Target
$123.33Price Target Upside60.17% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)0.84
Revenue Forecast (FY)$454.29M
Bulls Say, Bears Say
Bulls Say
Revenue Inflection & Margin ExpansionA meaningful revenue inflection with materially higher gross margins and a move to positive EBIT/net income signals improved unit economics. Durable margin expansion increases internal funding capacity for R&D and commercialization and reduces dependence on external financing over the medium term.
Strong Balance Sheet And Cash GenerationA large cash balance combined with positive operating cash after capex provides multi-quarter cushion to execute clinical programs and commercial expansion. Sustained positive cash generation reduces refinancing risk and supports discretionary investments while the business scales.
Improved Market Access Via Payer ContractsSecuring in‑network agreements with major payers and broad contracted lives is a structural advantage: it supports higher ASPs, faster adoption, and more predictable reimbursement. This strengthens long-term commercial traction and raises barriers for competitors seeking similar access.
Bears Say
Dependence On Medicare Coverage For OncologyOncology economics and ASP sustainability hinge on obtaining Medicare coverage. A delayed or unfavorable decision would reduce addressable reimbursement and could force lower pricing or limit adoption, materially slowing oncology margin normalization and multi-year revenue potential.
Oncology Margin Pressure And Scale RiskAs oncology grows from a small base, its lower margins can dilute companywide profitability unless scale and reimbursement improve. Persistent subscale mix or higher COGS tied to oncology workflows could compress long-term blended gross margins and weaken sustainable earnings power.
Revenue Recognition And AR Timing VolatilityMaterial true‑ups and rising AR tied to new payer contracts create quarter‑to‑quarter revenue recognition and cash timing variability. Persistent recognition volatility can obscure underlying demand, stress working capital, and complicate forecasting of sustainable free cash flow over the coming quarters.
BillionToOne, Inc. Class A News
BLLN FAQ
What was BillionToOne, Inc. Class A’s price range in the past 12 months?
BillionToOne, Inc. Class A lowest stock price was $61.96 and its highest was $138.70 in the past 12 months.
What is BillionToOne, Inc. Class A’s market cap?
BillionToOne, Inc. Class A’s market cap is $3.96B.
When is BillionToOne, Inc. Class A’s upcoming earnings report date?
BillionToOne, Inc. Class A’s upcoming earnings report date is Dec 15, 2026 which is in 205 days.
How were BillionToOne, Inc. Class A’s earnings last quarter?
BillionToOne, Inc. Class A released its earnings results on May 06, 2026. The company reported $0.34 earnings per share for the quarter, beating the consensus estimate of $0.031 by $0.309.
Is BillionToOne, Inc. Class A overvalued?
According to Wall Street analysts BillionToOne, Inc. Class A’s price is currently Undervalued.
Does BillionToOne, Inc. Class A pay dividends?
BillionToOne, Inc. Class A does not currently pay dividends.
What is BillionToOne, Inc. Class A’s EPS estimate?
BillionToOne, Inc. Class A’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BillionToOne, Inc. Class A have?
BillionToOne, Inc. Class A has 41,442,833 shares outstanding.
What happened to BillionToOne, Inc. Class A’s price movement after its last earnings report?
BillionToOne, Inc. Class A reported an EPS of $0.34 in its last earnings report, beating expectations of $0.031. Following the earnings report the stock price went up 14.128%.
Which hedge fund is a major shareholder of BillionToOne, Inc. Class A?
Currently, no hedge funds are holding shares in BLLN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BillionToOne, Inc. Class A Stock Smart Score
Company Description
BillionToOne, Inc. Class A
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from a maternal blood draw; Northstar Select, a liquid biopsy test that provides a list of mutations that are present in the tumor and types of mutations detected that include deletions, insertions, and point mutations; and Northstar Response, a test that provides longitudinal determination of cancer burden through methylation assessment. The company was incorporated in 2016 and is headquartered in Menlo Park, California.
BLLN Company Deck
BLLN Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive operational and financial performance: very high revenue and volume growth (84% and 44% YoY), expanded ASPs and gross margins (73%), attainment of GAAP profitability and positive cash, major payer wins (Anthem, United), and notable product innovation (Unity Confirm, MRD roadmap). Primary risks noted were margin pressure as oncology scales without Medicare coverage, timing/recognition volatility from true-ups and AR, and multi-year clinical and reimbursement timelines for certain products. On balance, the positives (robust growth, profitability, payer access, new product launches, upgraded guidance, strong cash position) materially outweigh the operational and timing risks cited.View all BLLN earnings summariesBLLN Stock 12 Month Forecast
Average Price Target
$123.33
▲(60.17% Upside)
Ownership Overview
20.06% Insiders
6.15% Mutual Funds
17.10% Other Institutional Investors
55.59% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---